CI Stock Recent News

The price-to-sales ratio is a convenient tool to gauge the value of stocks incurring losses or in an early development cycle. Stocks like TAP, PAGS, CI, STT and FHN hold promise.

Investors interested in Medical - HMOs stocks are likely familiar with Cigna (CI) and Humana (HUM). But which of these two stocks offers value investors a better bang for their buck right now?

Hospital revenue has grown by nearly 8% year-to-date in 2024. While hospital and medical costs are aiming to moderate, what does this entail for healthcare stocks and the sector at large?

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Here is how Cigna (CI) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year.

Cigna (CI) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Sarah James, Cantor Fitzgerald managing director, joins 'Power Lunch' to discuss the economic ecosystem for health insurers.

Cigna (CI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Positive guidance is one of the most bullish announcements shareholders can hear, injecting confidence in the future picture. And that's precisely what these three companies have announced.

Growing customer base and M&A strategies are likely to aid the Medical-HMO industry. However, escalating expenses and a dearth in the availability of medical personnel are concerning.